{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-018793","form_type":"8-K","ticker":"XFOR","cik":"0001501697","company_name":"X4 Pharmaceuticals, Inc","filed_at":"2024-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.700334+00:00","generated_at":"2026-06-03T05:30:10.648564+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"FDA approves X4 Pharma's XOLREMDI for WHIM syndrome; pricing set at $496,400/yr","bullets":["XOLREMDI (mavorixafor) approved for WHIM syndrome patients aged 12+ to increase neutrophils and lymphocytes.","Wholesale acquisition cost: $496,400/yr (patients >50 kg, 400 mg daily) and $372,300/yr (≤50 kg, 300 mg daily).","Launch through specialty pharmacy PANTHERx Rare; X4Connect support program offers copay assistance and insurance help.","Corporate presentation posted on company website providing business updates."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-018793","json":"https://secwatch.observer/filing/0001628280-24-018793.json","markdown":"https://secwatch.observer/filing/0001628280-24-018793.md","text":"https://secwatch.observer/filing/0001628280-24-018793.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024018793/0001628280-24-018793-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024018793/xfor-20240429.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T05:30:10.648564+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}